Lineage Cell Therapeutics (LCTX) Receivables (2011 - 2026)
Lineage Cell Therapeutics (LCTX) reported Receivables of $1.4 million for Q1 2026, up 553.05% on a YoY basis from $213000.0 in Q1 2025, and down 10.95% quarter-over-quarter from $1.6 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Receivables (2011 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Receivables for 16 years, with the latest figure at $1.4 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables rose 553.05% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 553.05% YoY), and the FY2025 full-year result was $1.6 million, up 144.83% from the prior year.
- Receivables for Q1 2026 stood at $1.4 million, down from $1.6 million in the prior quarter.
- The five-year high for Receivables was $1.6 million in Q4 2025, with the low at $77000.0 in Q1 2024.
- Historically, Receivables has averaged $594705.9 across 5 years, with a median of $432000.0 in 2023.
- The largest YoY upside for Receivables was 1140.51% in 2022 against a maximum downside of 98.28% in 2022.
- Lineage Cell Therapeutics' Receivables stood at $881000.0 in 2022, then slipped by 20.54% to $700000.0 in 2023, then fell by 8.86% to $638000.0 in 2024, then jumped by 144.83% to $1.6 million in 2025, then declined by 10.95% to $1.4 million in 2026.
- The last three Receivables figures came in at $1.4 million (Q1 2026), $1.6 million (Q4 2025), and $676000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | 1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 676,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Mar 31, 2025 | 213,000.00 |
| Dec 31, 2024 | 638,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Dec 31, 2023 | 700,000.00 |
| Sep 30, 2023 | 432,000.00 |
| Jun 30, 2023 | 406,000.00 |
| Mar 31, 2023 | 203,000.00 |
| Dec 31, 2022 | 881,000.00 |
| Sep 30, 2022 | 980,000.00 |
| Jun 30, 2022 | 732,000.00 |
| Mar 31, 2022 | 323,000.00 |
| Dec 31, 2021 | 51.18 Mn |
| Sep 30, 2021 | 79,000.00 |
| Jun 30, 2021 | 326,000.00 |